focus -WSS

focus

author：focus 2025-09-28 21:05:17 - browse：9

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Amylyx's ALS drug launch starts strong. It could be trouble for FDA

focus

WSS

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Maui's cultural, historic landmarks damaged in the devastating wildfires

Life sciences investors close nearly $6 billion in new funds

Key Senate panel to consider PBM, drug pricing reform package

Lung cancer screening guidelines updated for cigarette smokers

Friends ask where James Watson's attitudes about race came from

explore

focus

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

Tori Bowie and the unacceptable rates of Black maternal death

Naloxone nonprofit donates 200,000 doses after FDA approval

United colonoscopy coverage change 'may cost lives,' doctors say

Drastic changes should bring profitability, startup health insurers say

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

NIH trials fail to test meaningful long Covid therapies, experts say

Heart attack and stroke risk calculators need revising

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

hotspot

Life sciences investors close nearly $6 billion in new funds

How to use technology to prevent future drug shortages

Bill would allow buprenorphine prescription for addiction via telehealth

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

A biotech analyst on neuroscience, placebo effect, not over

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

hotspot

explore

focus

hotspot